RxDoctor Payments Data

Terra Oney, NP

Family · Huntington, WVNPI 1255687539

Payments from drug & device makers

$3,850in general payments, 2019–2025

Across 152 payments — averaging $25.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Novo Nordisk$705
  • Abbott$457
  • Lilly USA, LLC$238
  • Sanofi-aventis U.S. LLC$92
  • AstraZeneca$48
  • plus $342 from 16 others

What the payments were for

  • Travel & lodging$1,60942%
  • Food & beverage$2,22958%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,850 in reported general payments places this provider in the 85th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$20,716
Medicare patients
159
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide213$431,707
MounjaroTirzepatide248$404,199
JardianceEmpagliflozin220$329,011
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog127$233,709
Tresiba Flextouch U-200Insulin Degludec95$194,843
TrulicityDulaglutide106$182,264
Tresiba Flextouch U-100Insulin Degludec94$126,025
FarxigaDapagliflozin Propanediol49$63,246
JanuviaSitagliptin Phosphate40$63,067
Novolog FlexpenInsulin Aspart126$43,976
RybelsusSemaglutide16$40,112
Fiasp FlextouchInsulin Aspart (Niacinamide)20$38,342
Lantus SolostarInsulin Glargine,hum.Rec.Anlog169$37,115
Humalog Kwikpen U-100Insulin Lispro61$33,826
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/718$31,901

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$238$586,463354 claims
Novo NordiskOzempic, Rybelsus, Novolog$705$487,526257 claims
AstraZenecaFarxiga$48$63,24649 claims
MerckJanuvia$16$63,06740 claims
AbbVieSynthroid, Armour Thyroid$37$12,207110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,507 family providers in West Virginia.

Other family in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →